Immunosuppression in sepsis: A novel understanding of the disorder and a new therapeutic approach

The Lancet Infectious Diseases

Volumn 13, Issue 3, 2013, Pages 260-268

  Hotchkiss, Richard S ^a   Monneret, Guillaume ^b   Payen, Didier ^c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 7;

ANTIGENICITY; APOPTOSIS; CYTOKINE PRODUCTION; GENE EXPRESSION; HOSPITAL INFECTION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE UNIT; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEPSIS; SPLEEN CELL; SURVIVAL; T LYMPHOCYTE;

ANTIGENS, CD274; CYTOKINES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; INTERLEUKIN-7; PROGRAMMED CELL DEATH 1 RECEPTOR; SEPSIS;

EID: 84874256945     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70001-X     Document Type: Review

References (84)

1. Cohen J, Opal S, Calandra T Sepsis studies need new direction. Lancet Infect Dis 2012, 12:503-505.
2. Wenzel RP, Edmond MB Septic shock: evaluating another failed treatment. N Engl J Med 2012, 366:2122-2124.
3. Williams SC After Xigris, researchers look to new targets to combat sepsis. Nat Med 2012, 18:1001.
4. Dolgin E Trial failure prompts soul-searching for critical-care specialists. Nat Med 2012, 18:1000.
5. Angus DC The search for effective therapy for sepsis: back to the drawing board?. JAMA 2011, 306:2614-2615.
6. Vincent JL The rise and fall of drotrecogin alfa (activated). Lancet Infect Dis 2012, 12:649-651.
7. Torgersen C, Moser P, Luckner G, et al. Macroscopic postmortem findings in 235 surgical intensive care patients with sepsis. Anesth Analg 2009, 108:1841-1847.
8. Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011, 306:2594-2605.
9. Meisel C, Schefold JC, Pschowski R, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009, 180:640-648.
10. Hall MW, Knatz NL, Vetterly C, et al. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med 2011, 37:525-532.
11. Unsinger J, McGlynn M, Kasten KR, et al. IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J Immunol 2010, 184:3768-3779.
12. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
13. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
14. Cheever MA Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008, 222:357-368.
15. Hotchkiss RS, Karl IE The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348:138-150.
16. van Dissel JT, van Langevelde P, Westendorp RG, Kwappenberg K, Frolich M Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 1998, 351:950-953.
17. Ertel W, Kremer JP, Kenney J, et al. Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood 1995, 85:1341-1347.
18. Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JM Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991, 88:1747-1754.
19. Rigato O, Salomao R Impaired production of interferon-gamma and tumor necrosis factor-alpha but not of interleukin 10 in whole blood of patients with sepsis. Shock 2003, 19:113-116.
20. Sinistro A, Almerighi C, Ciaprini C, et al. Downregulation of CD40 ligand response in monocytes from sepsis patients. Clin Vaccine Immunol 2008, 15:1851-1858.
21. Weighardt H, Heidecke CD, Emmanuilidis K, et al. Sepsis after major visceral surgery is associated with sustained and interferon-gamma-resistant defects of monocyte cytokine production. Surgery 2000, 127:309-315.
22. Barochia AV, Cui X, Vitberg D, et al. Bundled care for septic shock: an analysis of clinical trials. Crit Care Med 2010, 38:668-678.
23. Monneret G, Venet F, Pachot A, Lepape A Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med 2008, 14:64-78.
24. Hotchkiss RS, Swanson PE, Freeman BD, et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 2009, 27:1230-1251.
25. Fink MP, Evans TW Mechanisms of organ dysfunction in critical illness: report from a round table conference held in Brussels. Intensive Care Med 2002, 28:369-375.
26. Abraham E, Singer M Mechanisms of sepsis-induced organ dysfunction. Crit Care Med 2007, 35:2408-2416.
27. Kethireddy S, Kumar A Mortality due to septic shock following early, appropriate antibiotic therapy: can we do better?. Crit Care Med 2012, 40:2228-2229.
28. Otto GP, Sossdorf M, Claus RA, et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit Care 2011, 15:R183.
29. Martin GS, Mannino DM, Moss M The effect of age on the development and outcome of adult sepsis. Crit Care Med 2006, 34:15-21.
30. Reber AJ, Chirkova T, Kim JH, et al. Immunosenescence and challenges of vaccination against influenza in the aging population. Aging Dis 2012, 3:68-90.
31. Meakins JL, Pietsch JB, Bubenick O, et al. Delayed hypersensitivity: indicator of acquired failure of host defenses in sepsis and trauma. Ann Surg 1977, 186:241-250.
32. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 2001, 166:6952-6963.
33. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Depletion of dendritic cells, but not macrophages, in patients with sepsis. J Immunol 2002, 168:2493-2500.
34. Felmet KA, Hall MW, Clark RS, Jaffe R, Carcillo JA Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. J Immunol 2005, 174:3765-3772.
35. Toti P, De Felice C, Occhini R, et al. Spleen depletion in neonatal sepsis and chorioamnionitis. Am J Clin Pathol 2004, 122:765-771.
36. Venet F, Chung CS, Monneret G, et al. Regulatory T cell populations in sepsis and trauma. J Leukoc Biol 2008, 83:523-535.
37. Venet F, Chung CS, Kherouf H, et al. Increased circulating regulatory T cells (CD4(+)CD25 (+)CD127 (-)) contribute to lymphocyte anergy in septic shock patients. Intensive Care Med 2009, 35:678-686.
38. Leng FY, Liu JL, Liu ZJ, Yin JY, Qu HP Increased proportion of CD4(+)CD25(+)Foxp3(+) regulatory T cells during the early-stage sepsis in ICU patients. J Microbiol Immunol Infect 2012, published online Aug 23. http://dx.doi.org/10.1016/j.jmii.2012.06.012.
39. Delano MJ, Scumpia PO, Weinstein JS, et al. MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med 2007, 204:1463-1474.
40. Hotchkiss RS, Swanson PE, Knudson CM, et al. Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. J Immunol 1999, 162:4148-4156.
41. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci USA 1999, 96:14541-14546.
42. Wesche-Soldato DE, Swan RZ, Chung CS, Ayala A The apoptotic pathway as a therapeutic target in sepsis. Curr Drug Targets 2007, 8:493-500.
43. Kollef KE, Schramm GE, Wills AR, Reichley RM, Micek ST, Kollef MH Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest 2008, 134:281-287.
44. Luyt CE, Combes A, Deback C, et al. Herpes simplex virus lung infection in patients undergoing prolonged mechanical ventilation. Am J Respir Crit Care Med 2007, 175:935-942.
45. Limaye AP, Kirby KA, Rubenfeld GD, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 2008, 300:413-422.
46. Xiao W, Mindrinos MN, Seok J, et al. A genomic storm in critically injured humans. J Exp Med 2011, 208:2581-2590.
47. Boomer JS, Shuherk-Shaffer J, Hotchkiss RS, Green JM A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis. Crit Care 2012, 16:R112.
48. Lukaszewicz AC, Grienay M, Resche-Rigon M, et al. Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction. Crit Care Med 2009, 37:2746-2752.
49. Venet F, Lepape A, Monneret G Clinical review: flow cytometry perspectives in the ICU - from diagnosis of infection to monitoring of injury-induced immune dysfunctions. Crit Care 2011, 15:231.
50. Guignant C, Lepape A, Huang X, et al. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit Care 2011, 15:R99.
51. Monneret G, Venet F Additional bad news from regulatory T cells in sepsis. Crit Care 2010, 14:453.
52. Belikova I, Lukaszewicz AC, Faivre V, Damoisel C, Singer M, Payen D Oxygen consumption of human peripheral blood mononuclear cells in severe human sepsis. Crit Care Med 2007, 35:2702-2708.
53. Sprent J, Surh CD Interleukin 7, maestro of the immune system. Semin Immunol 2012, 24:149-150.
54. Mackall CL, Fry TJ, Gress RE Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 2011, 11:330-342.
55. Kim HR, Hwang KA, Park SH, Kang I IL-7 and IL-15: biology and roles in T-cell immunity in health and disease. Crit Rev Immunol 2008, 28:325-339.
56. Morre M, Beq S Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival. Target Oncol 2012, 7:55-68.
57. Rosenberg SA, Sportes C, Ahmadzadeh M, et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 2006, 29:313-319.
58. Levy Y, Sereti I, Tambussi G, et al. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis 2012, 55:291-300.
59. Pellegrini M, Calzascia T, Toe JG, et al. IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell 2011, 144:601-613.
60. Kasten KR, Prakash PS, Unsinger J, et al. Interleukin-7 (IL-7) treatment accelerates neutrophil recruitment through gamma delta T-cell IL-17 production in a murine model of sepsis. Infect Immun 2010, 78:4714-4722.
61. Patel A, Patel J, Ikwuagwu J A case of progressive multifocal leukoencephalopathy and idiopathic CD4+ lymphocytopenia. J Antimicrob Chemother 2010, 65:2697-2698.
62. Unsinger J, Burnham CA, McDonough J, et al. Interleukin-7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis. J Infect Dis 2012, 206:606-616.
63. Venet F, Foray AP, Villars-Mechin A, et al. IL-7 restores lymphocyte functions in septic patients. J Immunol 2012, 189:5073-5081.
64. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001, 291:319-322.
65. Keir ME, Butte MJ, Freeman GJ, Sharpe AH PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26:677-704.
66. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354.
67. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007, 8:239-245.
68. Huang X, Venet F, Wang YL, et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci USA 2009, 106:6303-6308.
69. Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol 2010, 88:233-240.
70. Zhang Y, Zhou Y, Lou J, et al. PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit Care 2010, 14:R220.
71. Docke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997, 3:678-681.
72. Nalos M, Santner-Nanan B, Parnell G, Tang B, McLean AS, Nanan R Immune effects of interferon gamma in persistent staphylococcal sepsis. Am J Respir Crit Care Med 2012, 185:110-112.
73. Jarvis JN, Meintjes G, Rebe K, et al. Adjunctive interferon-γ immunotherapy for treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS 2012, 26:1105-1113.
74. Inoue S, Unsinger J, Davis CG, et al. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. J Immunol 2010, 184:1401-1409.
75. Adler G, Steeg C, Pfeffer K, et al. B and T lymphocyte attenuator restricts the protective immune response against experimental malaria. J Immunol 2011, 187:5310-5319.
76. Shubin NJ, Chung CS, Heffernan DS, Irwin LR, Monaghan SF, Ayala A BTLA expression contributes to septic morbidity and mortality by inducing innate inflammatory cell dysfunction. J Leukoc Biol 2012, 92:593-603.
77. Hotchkiss RS, Opal S Immunotherapy for sepsis-a new approach against an ancient foe. N Engl J Med 2010, 363:87-89.
78. Ward PA Immunosuppression in sepsis. JAMA 2011, 306:2618-2619.
79. Christaki E, Anyfanti P, Opal SM Immunomodulatory therapy for sepsis: an update. Expert Rev Anti Infect Ther 2011, 9:1013-1033.
80. Stearns-Kurosawa DJ, Osuchowski MF, Valentine C, Kurosawa S, Remick DG The pathogenesis of sepsis. Annu Rev Pathol 2011, 6:19-48.
81. Waterer GW Community-acquired pneumonia: genomics, epigenomics, transcriptomics, proteomics, and metabolomics. Semin Respir Crit Care Med 2012, 33:257-265.
82. Roger T, Lugrin J, Le Roy D, et al. Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood 2011, 117:1205-1217.
83. Nelson S, Belknap SM, Carlson RW, et al. A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. J Infect Dis 1998, 178:1075-1080. on behalf of the CAP Study Group.
84. Root RK, Lodato RF, Patrick W, et al. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med 2003, 31:367-373.